Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disease of unknown etiology. Recently, it has been reported that imatinib mesylate (Gleevec), an inhibitor of Bcr-Abl kinase useful in the treatment of chronic myeloid leukemia, is also effective in treating HES; however, the molecular target of imatinib in HES is unknown. This report identifies a genetic rearrangement in the eosinophilic cell line EOL-1 that results in the expression of a fusion protein comprising an N-terminal region encoded by a gene of unknown function with the GenBank accession number NM030917 and a C-terminal region derived from the intracellular domain of the platelet-derived growth factor receptor ␣ (PDGFR␣). The fusion gene was also detected in blood cells from two patients with HES. We propose naming NM030917 Rhe for Rearranged in hypereosinophilia. Rhe-PDGFR␣ fusions result from an apparent interstitial deletion that links Rhe to exon 12 of PDGFR␣ on chromosome 4q12. The fusion kinase Rhe-PDGFR␣ is constitutively phosphorylated and supports IL-3-independent growth when expressed in BaF3 cells. Proliferation and viability of EOL-1 and BaF3 cells expressing Rhe-PDGFR␣ are ablated by the PDGFR␣ inhibitors imatinib, vatalanib, and THRX-165724.
Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disease of unknown etiology. Recently, it has been reported that imatinib mesylate (Gleevec), an inhibitor of Bcr-Abl kinase useful in the treatment of chronic myeloid leukemia, is also effective in treating HES; however, the molecular target of imatinib in HES is unknown. This report identifies a genetic rearrangement in the eosinophilic cell line EOL-1 that results in the expression of a fusion protein comprising an N-terminal region encoded by a gene of unknown function with the GenBank accession number NM030917 and a C-terminal region derived from the intracellular domain of the platelet-derived growth factor receptor ␣ (PDGFR␣). The fusion gene was also detected in blood cells from two patients with HES. We propose naming NM030917 Rhe for Rearranged in hypereosinophilia. Rhe-PDGFR␣ fusions result from an apparent interstitial deletion that links Rhe to exon 12 of PDGFR␣ on chromosome 4q12. The fusion kinase Rhe-PDGFR␣ is constitutively phosphorylated and supports IL-3-independent growth when expressed in BaF3 cells. Proliferation and viability of EOL-1 and BaF3 cells expressing Rhe-PDGFR␣ are ablated by the PDGFR␣ inhibitors imatinib, vatalanib, and THRX-165724. P ersistent nonreactive hypereosinophilia, defined as an unexplained elevated eosinophil count (Ͼ1.5 ϫ 10 9 per liter) sustained for Ͼ6 months, characterizes both chronic eosinophilic leukemia (CEL) and idiopathic hypereosinophilic syndrome (HES). Tissue damage, resulting from direct infiltration by eosinophils and cytokine release, leads to progressive organ dysfunction that may be fatal. Increased marrow blasts, or the presence of a clonal cytogenetic abnormality, distinguishes CEL from HES. When clonality cannot be demonstrated, the diagnosis of HES further requires the exclusion of secondary eosinophilia, such as is seen in parasitic infection, collagen vascular disease, and neoplastic disorders (1) .
It has recently been reported that some patients with HES respond to the tyrosine kinase-inhibitor imatinib (Gleevec; refs. [2] [3] [4] [5] . Imatinib has emerged as a promising new therapy for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The antitumor effect of imatinib derives from its ability to inhibit aberrant, constitutively activated tyrosine kinases: the Bcr-Abl and Tel-PDGFR␤ (PDGFR, platelet-derived growth factor receptor) fusion kinases found in CML and some cases of chronic myelomonocytic leukemia, respectively, as well as the receptor tyrosine kinases c-Kit and PDGFR␣, which harbor activating mutations in GIST (6) (7) (8) (9) (10) . The efficacy of imatinib in HES suggests the involvement of an activated tyrosine kinase in this disease. Here we report the identification and characterization of a fusion kinase that is likely to be the target for imatinib in at least some HES patients.
Materials and Methods
Compounds. Imatinib mesylate was extracted from capsules of Gleevec. Vatalanib was prepared according to the published procedure (11) . THRX-165724 was prepared by coupling piperazine to the carboxyl group of SU6668 (12) .
cDNA Cloning, Plasmids, and Oligos. Total RNA was isolated from 5 ϫ 10 7 EOL-1 cells by using the RNeasy kit (Qiagen, Valencia, CA). Then 100 ng of total RNA was used to make cDNA in a volume of 20 l with a reverse oligonucleotide that primes in the 3Ј untranslated region of PDGFR␣ [5Ј-tccgcattgcaataaagtgg-3Ј (bases 3478-3459, GenBank accession no. M22734)] and the Thermoscript RT-PCR system (GIBCO͞BRL). Two microliters of the cDNA solution served as template in a 100-l PCR reaction to amplify full-length Rhe-PDGFR␣ [forward oligo, 5Ј-gttgcgctcggggcggccat-3Ј (bases 150 -169, accession no. NM030917); reverse oligo, 5Ј-ttctgaacgggatccagagg-3Ј (bases 3456-3437, accession no. M22734)]. The PCR fragment was isolated by agarose gel electrophoresis, cloned into the TOPO PCR vector (Invitrogen), and sequenced. The error-free sequence of a splice variant lacking the two observed alternatively spliced exons was cloned into the mammalian expression vector pcDNA 3.1(ϩ) (Invitrogen). Patient cDNA was generated as described above, using random hexamers or the specific PDGFR␣ primers 5Ј-ggatgtcggaatatttagaa-3Ј and 5Ј-gcagaaaggtactgcctttc-3Ј. To analyze patient cDNA for Rhe-PDGFR␣ fusion transcripts the following primer pair was used: Rhe forward, 5Ј-aattatgggtttaatgaag-3Ј (bases 651-699, accession no. NM030917); and PDGFR␣ reverse, 5Ј-aactttcatgacaggttgg-3Ј (bases 2000-1982, accession no. M22734). For the PCR analysis of the genomic fusion point in EOL-1 as well as the two patients, an oligonucleotide priming 3Ј of PDGFR␣ exon 12 in the reverse orientation was combined with the following specific forward primers: PDGFR␣ genomic reverse, 5Ј-ttcttactaagcacaagctcagatc-3Ј (bases 13912-13888, accession no. AC098587); EOL-1 and patient 3 genomic forward, 5Ј-aagcatctaattaggtgaaactg-3Ј (bases 48554-48576, accession no. NT022853); and patient 1 genomic forward, 5Ј-cagggaagaactggaaactc-3Ј (bases 22466-22485, accession no. NT022853).
Cells and Cell Lines. The EOL-1 and BaF3 cell lines were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany). The basic culture medium for the EOL-1 and BaF3 cell lines was RPMI 1640 (GIBCO͞BRL) supplemented with 10% FBS, 100 units͞ml penicillin, and 100 units͞ml streptomycin. The medium for BaF3 cells was also supplemented with 1 ng͞ml IL-3 (BioSource International, Camarillo, CA). A BaF3 cell line expressing Rhe-PDGFR␣ was created by electroporation of BaF3 cells at 300 mV͞960 F. After electroporation, the BaF3 cells were maintained in IL-3-containing medium for 48 h, selected in IL-3-containing medium plus 1 mg͞ml G418 for 10 days, and subcloned by limiting dilution.
Cell Viability Assays. Cell viability was assessed by tetrazolium salt reduction using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay (Roche). In a 96-well plate, 5 ϫ 10 4 cells per well were plated in the presence of serial dilutions of compounds. The cells were incubated for 72 h before the addition of MTT substrate.
Immunoprecipitation and Western Blotting. Antibodies against PDGFR␣͞␤ and against phosphotyrosine (4G10) were purchased from Upstate Biotechnology (Lake Placid, NY). For each immunoprecipitation, 1 ϫ 10 7 cells were lysed in 0.75 ml of modified RIPA buffer [50 mM Tris⅐HCl, pH 7.4͞1% Nonidet P-40͞150 mM NaCl͞1 mM EDTA͞1 mM Na 3 VO 4 and protease inhibitor mixture (Roche)]. The lysates were incubated with the appropriate antibody and protein G beads (Sigma) overnight at 4°C. The immunocomplexes were recovered by centrifugation, washed with RIPA buffer, boiled in sample buffer, and resolved by SDS͞PAGE. The proteins were transferred to a poly(vinylidene difluoride) (PVDF) membrane (Invitrogen), blocked with PBS͞0.1% Tween 20͞3% BSA, and probed with a specific antibody for 3 h at room temperature. Subsequently, the blots were washed with PBS͞0.1% Tween 20. Specific antibody binding was detected with a horseradish peroxidase-coupled secondary antibody, followed by enhanced chemiluminescence (ECL, Amersham Biosciences) and exposure to film. The primary antibody was typically stripped with ImmunoPure IgG Elution Buffer (Pierce) for reprobing of the blot with a second antibody.
Phosphorylation Inhibition Assay. Cells (1 ϫ 10 7 ) were incubated in 3 ml of media with the indicated concentration of drug for 1 h. The cells were subsequently lysed and immunoprecipitated with the appropriate antibody. Then, SDS͞PAGE was performed, followed by immunoblotting with the antiphosphotyrosine antibody 4G10.
Protein Digestion and Peptide Analysis. This work was performed by Proteomic Research Services (Ann Arbor, MI). The sample was provided to Proteomic Research Services in the form of 50 l of protein G immunoaffinity resin, to which was bound tyrosine phosphoproteins from 1 ϫ 10 8 EOL-1 cells via antibody 4G10. The proteins were fractionated by SDS͞PAGE and visualized by staining with SYPRO Ruby (Molecular Probes). Plugs were chosen for excision based on an overlay of the SYPROstained lane with that of a companion lane visualized by Western blotting with 4G10. The plugs were subjected to in-gel digestion with trypsin (ProGest, Ann Arbor, MI), and a portion of the supernatant was used for analysis by matrix-assisted laser desorption ionization (MALDI)͞MS. MALDI͞MS data were acquired on an Applied Biosystems Voyager DE-STR instrument, and the observed m͞z values were submitted to a search for peptide mass fingerprints by the software package PROFOUND (Proteometrics, Ann Arbor, MI), querying the NCBInr database. In cases where MALDI͞MS analysis was inconclusive, samples were analyzed by nano-liquid chromatography followed by two-dimensional MS (LC͞MS͞MS) on a Micromass (Manchester, U.K.) Q-Tof2 instrument. The MS͞MS data were searched by using the search engine MASCOT from Matrix Science (www.matrixscience.com).
Results
Model Cell Line EOL-1. EOL-1 is a cell line derived from the blood of a 33-year old man with acute eosinophilic leukemia following hypereosinophilic syndrome. The EOL-1 cell line has been characterized as having a hyperdiploid karyotype with a range of 48-51 chromosomes per cell: 50,XY,ϩ4,ϩ6,ϩ8,del(9)(q22),ϩ19. Imatinib and two other inhibitors of the PDGFR tyrosine kinase family (vatalanib and THRX-165724, Fig. 1 ) potently reduce the viability of EOL-1 cells (Fig. 2) . Common targets inhibited by imatinib, vatalanib, and THRX-165724 include PDGFR␣ and -␤, as well as c-Kit (13, 14) .
Identification of a Tyrosine Phosphoprotein in EOL-1 Cells.
A common pathway for cellular transformation has been shown to result from mutations in protein kinases that lead to their constitutive activation and autophosphorylation. To identify a potentially autophosphorylated mutant kinase in EOL-1 cells, tyrosine phosphorylated proteins were immunoprecipitated from a cell extract and visualized by immunoblotting. This revealed a very prominent phosphoprotein of apparent molecular weight 110 kDa (data not shown). When cells were treated with imatinib before lysis, the prominent 110-kDa phosphoprotein and minor phosphoproteins were no longer observed. The imatinib targets PDGFR␣ (170 kDa) and -␤ (190 kDa), as well as c-Kit (145 kDa), have molecular weights that are larger than 110 kDa. To identify the 110-kDa protein, the protein was subjected to in-gel tr yptic digestion. Tr yptic peptides were analyzed by MALDI͞MS and LC͞MS͞MS, and queries for peptide mass fingerprints were made against the NCBInr database. This provided matches to peptides from three proteins: (i) nucleolin, (ii) the protein predicted for the gene with accession number NM030917, and (iii) PDGFR␣. Nucleolin is a 105-kDa phosphoprotein involved in ribosome assembly. It is not a kinase and, therefore, is an unlikely target for imatinib. NM030917 codes for a protein with unknown function. Although PDGFR␣ is a known target of imatinib, its apparent molecular weight is 170 kDa rather than 110 kDa. Interestingly, all 10 of the PDGFR␣ peptides mapped to the C-terminal cytoplasmic region of the receptor that contains the kinase domain, and all 8 peptides of the protein encoded by NM030917 mapped to its N-terminal region.
Identification of a Genomic Deletion, Fusion Gene, and Fusion Protein in EOL-1 Cells. The genes for NM030917 and PDGFR␣ are located in close proximity on chromosome 4q11-12 (separated by Ϸ800 kb). This proximity raised the possibility that a fusion kinase comprising these two proteins, caused by a submicroscopic rearrangement of a small portion of chromosome 4, exists in EOL-1 cells. To determine whether NM030917 and PDGFR␣ are fused in EOL-1, oligonucleotides were designed to prime from the 5Ј end of NM030917 and the 3Ј end of PDGFR␣.
RT-PCR was performed by using total RNA isolated from EOL-1 cells, resulting in the selective amplification of a 2.5-kb product. This fragment was cloned and multiple clones were sequenced. The 2.5-kb product indeed encompasses a NM030917-PDGFR␣ fusion transcript (Fig. 3A) . Four different splice variants were observed among the sequenced clones, all of which occur in the NM030917 segment. The fusion gene encodes predicted proteins of 811-849 aa (Fig. 3B) . A tryptic peptide (ANENSNIQLPYDSR) spanning the predicted fusion junction was observed by ion spray MS. We have termed the gene represented by NM030917 ''Rhe,'' for Rearranged in hypereosinophilia. By using oligonucleotides that primed 5Ј and 3Ј of the fused exonic sequences of Rhe and PDGFR␣, respectively, a fragment was amplified from genomic DNA that contained the EOL-1 chromosomal breakpoint. Rhe is contained in the genomic sequence NT022853 from position 1583318-1666068. Seventeen exons have been assigned in this sequence by the NCBI. According to these assignments, the break in EOL-1 occurs in the intron following exon 11 of Rhe and is fused within exon 12 of PDGFR␣ (15) . The fusion transcript is in-frame (Fig. 4A) . The splicing process uses the first AG in the PDGFR␣ exon 12 fragment as a splice acceptor site for intron 11 of Rhe (Fig. 4B) .
Identification of Rhe-PDGFR␣ in HES Patient Cells. To determine whether the Rhe-PDGFR␣ fusion was present in HES patients, blood cells from four patients diagnosed with HES were obtained (for patient descriptions, see Supporting Text, which is published as supporting information on the PNAS web site, www.pnas.org). Patients 1 and 2 have been treated with imatinib. Patient 1 responded to treatment, but patient 2 did not. After showing a complete hematologic remission, patient 1 relapsed and died. This patient had multiple clonal cytogenetic abnormalities that led to the diagnosis of CEL. Genomic DNA as well as total RNA and cDNA were prepared from all patient cells except for patient 1, from whose cells only genomic DNA (no RNA or cDNA) was obtained before imatinib treatment. The cDNA samples were subjected to PCR with a primer pair spanning the fusion point determined in EOL-1 cells. In the samples from patients 1 (relapsed) and 3, fragments could be amplified from the cDNA that constituted in-frame fusion transcripts between Rhe and PDGFR␣ (Fig. 4A) . No Rhe-PDGFR␣ fusion was detected in patients 2 and 4. In patient 1, the fusion transcript connects exon 8 of Rhe within exon 12 of PDGFR␣. A similar approach as for EOL-1 was used to identify the genomic breakpoint. In patient 1, the intronic break is at an AG dinucleotide that serves as the splice acceptor site so that exon 8 in Rhe and part of exon 12 in PDGFR␣ are fused in-frame in the fusion transcript (Fig. 4B) . The Rhe-PDGFR␣ fusion in patient 1 was detected in genomic DNA preparations derived from cells taken before the start of imatinib therapy and at the time of relapse. The analysis of Rhe-PDGFR␣ cDNA at the time of relapse revealed a point mutation in the PDGFR␣ kinase domain. The mutation affects amino acid position 674 in PDGFR␣, resulting in the substitution of threonine by isoleucine (T674I; Fig. 4C ).
In patient 3, the fusion transcript and the genomic break are identical to the mutation found in EOL-1 cells (Fig. 4 A and B) .
Inhibition of Rhe-PDGFR␣. Rabbit antiserum raised against a peptide derived from the cytoplasmic domain of PDGFR␣ successfully immunoprecipitated the 110-kDa phosphoprotein from an EOL-1 cell extract. Treatment of the cells with imatinib, vatalanib, and THRX-165724 resulted in dose-dependent inhibition of phosphorylation of the fusion protein (Fig. 5) . In the case of vatalanib and THRX-165724, the potency of inhibition of phosphorylation (IC 50 of 300 and 30 nM, respectively) corresponds closely to the potencies in inducing apoptosis (IC 50 of 140 and 25 nM, respectively). Imatinib is considerably more potent in inducing apoptosis of EOL-1 cells (IC 50 ϭ 0.5 nM) than it is in inhibiting the phosphorylation of the fusion protein (IC 50 ϭ 30 nM) (Fig. 5A) . When the phosphotyrosine blots were reprobed with an antibody against PDGFR␣, multiple bands were visible. These bands likely represent proteins resulting from the various splice forms of Rhe-PDGFR␣. Given the relatively sharp phosphotyrosine band, not all Rhe-PDGFR␣ proteins derived from different splice forms may be phosphorylated.
Cell-Transforming Potential of Rhe-PDGFR␣. Mutationally activated tyrosine kinases, as found in many cancers, can transform the murine myeloid cell line BaF3 to interleukin-3 independence. To determine whether Rhe-PDGFR␣ has the ability to transform cells, a BaF3 cell line was established. BaF3 cells expressing Rhe-PDGFR␣ from EOL-1 were found to be IL-3-independent. The fusion protein in these cells was constitutively phosphorylated, and the phosphorylation was inhibited by imatinib with an IC 50 of 30 nM, the same value as obtained in EOL-1 (Fig. 5B) . Inhibition with imatinib, vatalanib, and THRX-165724 resulted in reduced viability of the BaF3 Rhe-PDGFR␣ cells, with IC 50 s similar to the potency of the drugs in EOL-1 (Fig. 6A) . The effect of the inhibitors was overcome in the presence of IL-3 (Fig. 6B) .
Discussion
We have identified and characterized a fusion gene and derived fusion kinase protein associated with idiopathic hypereosinophilia by using the EOL-1 cell line. This cell line is derived from a HES patient who had developed AML. Patients with HES are known to develop clonal cytogenic abnormalities, AML, or granulocytic sarcoma (1). We found that the viability of EOL-1 cells was exquisitely sensitive to imatinib, with an IC 50 of only 0.5 nM in an MTT viability assay. This finding is consistent with clinical reports of the potency of imatinib in treating HES (2-5). We also noticed that EOL-1 cells were sensitive to two other tyrosine kinase inhibitors, vatalanib and THRX-165724, albeit at higher concentrations.
EOL-1 cells were found to express a 110-kDa phosphoprotein, the phosphorylation of which was inhibited when the cells were treated with imatinib. Because constitutively activated mutant kinases are often highly phosphorylated, we isolated the 110-kDa phosphoprotein. Mass spectrometric analysis of tryptic peptides revealed peptides matching sequences predicted for the N-terminal segment of the protein encoded by NM030917 and peptides matching sequences from the C-terminal segment of PDGFR␣. Because NM030917 and PDGFR␣ are located in close proximity on chromosome 4, we postulated that a chromosomal rearrangement, such as a small interstitial deletion, could have produced a fusion of these two genes without being detectable by karyotype analysis. Amplification, cloning, and sequencing of cDNAs encoding four splice variants of such a fusion from EOL-1 cells confirmed this deletion. NM030917-PDGFR␣ fusion genes were also found in the blood samples from two HES patients. We suggest naming the gene coding for NM030917 ''Rearranged in hypereosinophilia,'' or Rhe. To our knowledge, Rhe-PDGFR␣ is the first fusion kinase derived from an intrachromosomal rearrangement rather than a chromosomal translocation.
Multiple lines of evidence support the assignment of the 110-kDa phosphoprotein in EOL-1 as Rhe-PDGFR␣. Based on the Rhe-PDGFR␣ cDNA, the corresponding protein has 849 amino acids with a predicted molecular weight of 95 kDa. This correlates well with the observed apparent molecular weight of 110 kDa for the phosphoprotein. A tryptic peptide derived from the isolated 110-kDa protein spans the predicted fusion junction of Rhe and PDGFR␣. Furthermore, the 110-kDa phosphoprotein could be immunoprecipitated with an antibody against the cytoplasmic domain of PDGFR␣. Rhe-PDGFR␣ is also likely to be the target for imatinib, vatalanib, and THRX-165724 in EOL-1 because the expression of the fusion gene conferred IL-3-independent growth to BaF3 cells that was inhibited by the three drugs at concentrations similar to those at which they inhibited the viability of EOL-1 cells. The viability of these BaF3 cells in the presence of the PDGFR␣ inhibitors could be maintained by exogenous IL-3.
The potencies of vatalanib and THRX-165724 in the viability and autophosphorylation assays are well correlated. In contrast, the viability of EOL-1 and BaF3 Rhe-PDGFR␣ cells is 100-fold more sensitive to imatinib than the inhibition of Rhe-PDGFR␣ autophosphorylation. The basis for this discrepancy is unknown; however, it might reflect differences in the rates of association of the different inhibitors with Rhe-PDGFR␣.
Amplification and sequencing of genomic DNA from EOL-1 cells revealed that the genomic breakpoint junctions fell within an intron following exon 11 of Rhe and within exon 12 of PDGFR␣. The same mutation was observed in patient 3, and a similar submicroscopic deletion was discovered in patient 1. In patient 1 the resulting transcript fused a different site in the Rhe gene to a distinct site in PDGFR␣ exon 12. Exon 12 encompasses the cytoplasmic juxtamembrane region of PDGFR␣, followed by the kinase domain.
Patient 1 relapsed and died after initially having shown a complete remission in response to imatinib. At the time of relapse, this patient had a T674I mutation in the PDGFR␣ kinase domain. T674 in PDGFR␣ corresponds to T315 in c-Abl. Based on the crystal structure of the catalytic domain of c-Abl bound to a derivative of imatinib, T315 forms part of the imatinib binding pocket and establishes a hydrogen bond with the drug (16) . The T315I mutation ablates the kinase inhibitory activity of imatinib for Bcr-Abl and is one of the most common mutations found in chronic myeloid leukemia (CML) patients who are resistant to the drug (17, 18) . We speculate, therefore, that the T674I mutation underlies the relapse of patient 1. If correct, this would provide further evidence that Rhe-PDGFR␣ is the target of imatinib. However, we lack a cDNA sample from this patient at the start of treatment that would allow us to test in the most relevant way whether the mutation is linked to resistance by becoming predominant in HES cells at the time of relapse. Two reports describe patients with myeloproliferative disorders with eosinophilia who have chromosomal translocations at 4q11-12 (19, 20) . These translocations may involve either Rhe or PDGFR␣, leading to different disease-promoting fusion proteins. For example, Rhe may play a role analogous to that played by Tel or Bcr: promoting dimerization and, thus, the activation of known oncogenic fusion kinases. Like PDGFR␣, the c-Kit gene is located on chromosome 4q12. Submicroscopic deletions could also result in Rhe-c-Kit fusions. A search of the NCBI EST database reveals that Rhe is expressed in many tissues and organs, suggesting that Rhe-fusion kinases may not be restricted to cells of hematological origin. The protein encoded by Rhe is homologous (26% over 307 residues) to yeast protein FIP1, a component of a polyadenylation factor (21) .
PDGFR␣ shares a high degree of homology with PDGFR␤ (22) . PDGFR␤ is a target for various chromosomal translocations in chronic myeloproliferative diseases that result in the expression of fusion kinases, e.g., Tel-PDGFR␤ and Rab5-PDGFR␤ (23) (24) (25) (26) (27) (28) . Like PDGFR␤, PDGFR␣ has recently been described as part of a fusion gene. Baxter et al. (29) identified two atypical CML patients with a t(4, 22)(q12:q11) translocation resulting in Bcr-PDGFR␣ fusions. Similar to the Rhe-PDGFR␣ fusion we have discovered, both Bcr-PDGFR␣ fusions involve translocation into exon 12 of PDGFR␣. Indeed, one of the two Bcr-PDGFR␣ fusions produces precisely the same PDGFR␣ fragment that we observed in Rhe-PDGFR␣ from EOL-1 cells.
In summary, we have shown that the Rhe-PDGFR␣ genomic rearrangement, discovered in the eosinophilic EOL-1 cell line, is present in a subset of patients diagnosed with HES. Cell viability and phosphorylation data suggest that the Rhe-PDGFR␣ kinase encoded by the fusion gene plays a central role in the disease process of these HES patients. A large number of HES͞CEL samples will have to be analyzed to establish the frequency of the fusion tyrosine kinase and its general relevance to the disease. We believe that HES in which the Rhe-PDGFR␣ fusion is detected could more accurately be described as CEL.
Note. While this paper was under review, Cools et al. (30) described a discovery of the same 4q12 deletion in patients with HES that we have described here. The authors named N⌴030917 Fip1L1 and the GenBank entry for NM030917 has been annotated accordingly. Hence, genetic fusions between NM030917 and PDGFR␣ should be referred to as Fip1L1-PDGFR␣.
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